 |
|
|
Important Notice: The Forum does not endorse any medical
product or therapy. ALL medications and supplements
should be taken ONLY under the supervision of a physician,
due to the possibility of side-effects, drug interactions,
etc.
|
Drug:
|
GTS-21 (DMXB-A) University of Florida
|
|
Mode of action:
|
nAChR agonist
|
|
Phase:
|
Phase 3
|
|
Company:
|
University of Florida
|
|
Note:
|
Proof-of-concept study successful
|
Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM,
Johnson L, Allensworth D, Guzman-Bonilla A, Clement B, Ball
MP, Kutnick J, Pender V, Martin LF, Stevens KE, Wagner BD,
Zerbe GO, Soti F, Kem WR. Initial phase 2 trial of a
nicotinic agonist in schizophrenia. Am J Psychiatry. 2008
Aug;165(8):1040-7. Abstract
Olincy A, Harris JG, Johnson LL, Pender V, Kongs S,
Allensworth D, Ellis J, Zerbe GO, Leonard S, Stevens KE,
Stevens JO, Martin L, Adler LE, Soti F, Kem WR, Freedman R.
Proof-of-concept trial of an alpha7 nicotinic agonist in
schizophrenia. Arch Gen Psychiatry . 2006 Jun 1 ; 63(6):630-8. Abstract
|
|
|
|
|
Text Size 
See our most recent Schizophrenia Bulletin theme Webinar: